New Agents for Targeting of IL-13RA2 Expressed in Primary Human and Canine Brain Tumors

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Debinski, Waldemar ^a   Dickinson, Peter ^b   Rossmeisl, John H ^c   Robertson, John ^c   Gibo, Denise M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PEPTIDE; CYTOTOXIN; GLUTAMIC ACID; INTERLEUKIN 13 RECEPTOR ALPHA2; LYSINE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; BINDING ASSAY; BRAIN TUMOR; CELL KILLING; CELL LYSATE; CELL SPECIFICITY; CHOROID PLEXUS PAPILLOMA; DOG; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MENINGIOMA; NONHUMAN; OLIGODENDROGLIOMA; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEIN TARGETING; SEQUENCE ANALYSIS; TISSUE SECTION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOGS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; IMMUNOPRECIPITATION; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 84885808163     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077719     Document Type: Article

References (41)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. doi:10.1056/NEJMoa043330. PubMed: 15758009.
2. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK, (1995) Human glioma cells overexpress receptor for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res 1: 1253-1258. PubMed: 9815919.
3. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY, (1999) Receptor for interleukin 13 is a marker and therapeutic target for human high grade gliomas. Clin Cancer Res 5: 985-990. PubMed: 10353730.
4. Mintz A, Gibo DM, Webb (Slagle) B, Debinski W (2002) IL13Rα2 is a glioma-restricted receptor for IL13. Neoplasia 4: 388-399.
5. Debinski W, (1998) An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link. Crit Rev Oncog 9: 255-268. PubMed: 10201630.
6. Debinski W, Gibo DM, (2000) Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med 6: 440-449. PubMed: 10952023.
7. Hu N, Gibo DM, Debinski W, (2005) Cytokine up-regulation of IL-13Rα2 in GBM cells leads to an increased potency of recombinant IL13 cytotoxin. Cancer Therapy 3: 531-542.
8. Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, et al. (2002) Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62: 3335-3339. PubMed: 12067969.
9. Mintz A, Debinski W, (2000) Cancer genetics/epigenetics and the X chromosome: Possible new links for malignant glioma pathogenesis and immune-based therapies. Critic Rev Oncogen 11: 77-95.
10. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H, (2002) Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor α2 chain. Clin Cancer Res 8: 2851-2855. PubMed: 12231526.
11. Mintz A, Gibo DM, Madhankumar AB, Cladel NM, Christensen ND, et al. (2008) Protein and DNA-based active immunotherapy targeting interleukin 13 receptor alpha 2. Cancer Biother Radiopharm 23: 581-589. doi:10.1089/cbr.2008.0462. PubMed: 18976118.
12. Zhou G, Ye G-J, Debinski W, Roizman B, (2002) Genetic engineering of a herpes virus 1 vector dependent on the IL-13Rα2 receptor for entry into cells: interaction of glycoprotein D with its receptors is independent of the fusion of the envelope and the plasma membrane. Proc Natl Acad Sci USA 99: 15124-15129. doi:10.1073/pnas.232588699. PubMed: 12417744.
13. Kahlon KS, Brown C, Cooper LJN, Raubitschek A, Forman SJ, et al. (2004) Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 64: 9160-9167. doi:10.1158/0008-5472.CAN-04-0454. PubMed: 15604287.
14. Chunbin L, Hall WA, Jin N, Todhunter DA, Panoskaltis-Mortari A, et al. (2002) Targeting glioblastoma multiforme with an IL-13/ diphtheria toxin fusion protein in vitro and in vivo in nude mice. Prot Engin 15: 419-427. doi:10.1093/protein/15.5.419.
15. Debinski W, Gibo DM, Kealiher A, Puri RK, (1998) Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotechnol 16: 449-453. doi:10.1038/nbt0598-449. PubMed: 9592393.
16. Mintz A, Gibo DM, Madhankumar AB, Debinski W, (2003) Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha-2-expressing glioma. J Neurooncol 64: 117-123. doi:10.1023/A:1024918916984. PubMed: 12952292.
17. Ulasov IV, Tyler MA, Han Y, Glasgow JN, Lesniak MS, (2007) Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma. Hum Gene Ther 18: 118-129. doi:10.1089/hum.2006.146. PubMed: 17328684.
18. Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, et al. (2010) Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci USA 107: 20021-20026. doi:10.1073/pnas.1008261107. PubMed: 21030678.
19. Wykosky J, Gibo DM, Stanton C, Debinski W, (2008) IL-13 Receptor alpha-2, EphA2, and Fra-1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res 14: 199-208. doi:10.1158/1078-0432.CCR-07-1990. PubMed: 18172271.
20. Fankhauser R, Luginbühl H, McGrath JT, (1974) Tumours of the nervous system. Bull World Health Organ 50: 53-69. PubMed: 4371739.
21. Priester WA, Mantel N, (1971) (Occurrence of tumors in domestic animals. Data from 12 United States and Canadian colleges of veterinary medicine. J Natl Cancer Inst 47: 1333-1344. PubMed: 5120412.
22. Schneider R, (1978) General considerations, in: Moulton JE, eds., Tumors in Domestic Animals, University of California Press, Berkley. pp. pp. 1-5.
23. Priester WA, McKay FW, (1980) The occurrence of tumors in domestic animals, Ziegler JL, eds. Monograph. Bethesda MD: US Dept of Health and Human Services. pp. pp. 1-210.
24. Hayes HM, Priester WA Jr, Pendergrass TW, (1975) Occurrence of nervous-tissue tumors in cattle, horses, cats and dogs. Int J Cancer 15: 39-47. doi:10.1002/ijc.2910150106. PubMed: 165149.
25. Luginbuhl H, Fankhauser R, McGrath JT, (1968) Spontaneous neoplasms of the nervous system of animals. Prog Neurology Surg 2: 85-164.
26. Rossmeisl JH Jr., Jones JC, Zimmerman KL, Robertson JL, (2013) Survival time following hospital discharge in dogs with palliatively treated primary brain tumors. J Am Vet Med Assoc 242: 193-198. doi:10.2460/javma.242.2.193. PubMed: 23276095.
27. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, et al. (2007) Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neuro Oncol 85: 133-148. doi:10.1007/s11060-007-9400-9. PubMed: 17874037.
28. Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Roberts B, et al. (2008) Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg 108: 989-998. doi:10.3171/JNS/2008/108/5/0989. PubMed: 18447717.
29. Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Larson RF, et al. (2010) Canine spontaneous glioma: a translational model system for convection-enhanced delivery. Neuro Oncol 12: 928-940.
30. Pluhar GE, Grogan PT, Seiler C, Goulart M, Santacruz KS, et al. (2010) Retrieved onpublished at whilst December(year 1111) from Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine 28: 3371-3378.
31. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109. doi:10.1007/s00401-007-0243-4. PubMed: 17618441.
32. York D, Higgins RJ, LeCouteur RA, Wolfe AN, Grahn R, et al. (2012) TP53 mutations in canine brain tumors. Vet Pathol 49: 796-801. doi:10.1177/0300985811424734. PubMed: 22002975.
33. Debinski W, Gibo DM, (2005). Retrieved onpublished at whilst December(year 1111) from Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res 3: 237-249.
34. Dickinson PJ, Roberts BN, Higgins RJ, Leutenegger CM, Bollen AW, et al. (2006) Expression of receptor tyrosine kinases Retrieved onpublished at whilst December year 1111 from VEGFR-1 (FLT-1), VEGFR-2 (KDR), EGFR-1, PDGFRalpha and c-Met in canine primary brain tumours.; Comp Vet Oncol. 4: 132-140.
35. Debinski W, Obiri NI, Pastan I, Puri RK, (1995) A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 270: 16775-16780. doi:10.1074/jbc.270.28.16775. PubMed: 7622490.
36. Joshi BH, Plautz GE, Puri RK, (2000). Retrieved onpublished at whilst December(year 1111) from Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 60: 1168-1172.
37. Balyasnikova IV, Wainwright DA, Solomaha E, Lee G, Han Y, et al. (2012) Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2. J Biol Chem 287(36):: 30215-30227. doi:10.1074/jbc.M112.370015. PubMed: 22778273.
38. Nguyen V, Conyers JM, Zhu D, Gibo DM, Dorsey JF, et al. (2011) Retrieved onpublished at whilst December(year 1111) from IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications. Transl Oncol 4: 390-400.
39. Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, et al. (2012) Stem-like tumor-initiating cells isolated from IL-13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res 18: 2199-2209. doi:10.1158/1078-0432.CCR-11-1669. PubMed: 22407828.
40. Binda E, Visioli A, Giani F, Lamorte G, Copetti M, et al. (2012) The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell 22(6):: 765-780. doi:10.1016/j.ccr.2012.11.005. PubMed: 23238013.
41. Sampson JH, Archer G, Pedain C, Wembacher-Schröder E, Westphal M, et al. (2010) Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg 113: 301-309. doi:10.3171/2009.11.JNS091052. PubMed: 20020841.